Oral diagnostic instrument

FIELD: medicine.

SUBSTANCE: instrument comprises an oral sample collection vessel, a detector able to detect a marker in this sample, an indicator actuated by a detector signal. The above vessel is detachably connected to an oral cavity instrument. The vessel comprises a sample collection element, a sample storage container, and a passage connecting the collection element and the container to supply the sample to the container by capillary action. The indicator is integrated into the container. The declared instrument is used to diagnose oral diseases by collecting the oral sample, detecting one or more markers in this sample and indicating the presence of one of the disease markers.

EFFECT: inventions enables establishing an accurate and fast diagnosis of the oral pathologies accompanying the daily oral care by placing the detector inside the container able to accumulate a required amount of the sample to be diagnosed.

25 cl, 1 dwg

 

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims the priority of Provisional Patent Application U.S. No. 61/289425, filed on December 23, 2009, which is incorporated in this application by reference.

The LEVEL of TECHNOLOGY

[0002] the problem of oral health can take many forms, such as caries, periodontal disease and bad breath. In many problems of oral health is the main role played by bacteria. For example, caries and periodontal disease is often caused by unwanted bacteria in the mouth. Bacteria also interact with proteins present in the saliva, with the formation of a film known as plaque, which covers the teeth. If this plaque is not removed, the acid produced by bacteria can affect the teeth, resulting in tooth decay. Plaque can also affect the soft gum tissue of the mouth, which leads to teeth loss in adults.

[0003] Previous attempts in systems determine the health of the oral cavity are widely used and have limited functionality. For example, test strips, using generally accepted approaches for diagnosing the risk of dental caries with the use of antibodies to detect the presence of bacteria of the oral cavity, has not achieved commercial success or widespread dissemination among the population. Moreover, the system, use the matter of color as an indicator of the presence of specific bacteria or enzymes, burdened by the need for additional processing or device, such as a colorimeter or fluorimetry, for the manifestation of color. In addition to the inconvenience of many stages, the use of additional drugs and equipment can increase the risk and increase the value.

[A] JP 2009-216496 discloses an electric toothbrush that contains the detector element. WO 2005/073721 discloses a test kit for the detection of periodontal disease. WO 2008/139324 discloses a device for taking a sample of fluid. US 2009/0193211 discloses a device for cleaning teeth containing gas detection system.

The INVENTION

[0004] Some embodiments of the presented invention provides a device for identifying the presence of pathological conditions of the oral cavity, comprising: a vessel to sample from the oral cavity; a detector capable of detecting the presence of a token in the specified form; and an indicator that is able to trigger due to the signal from the detector.

[0005] Additional embodiments of provide a way to identify the presence of pathological conditions of the oral cavity of a subject, comprising: taking a sample from the oral cavity of a subject with the use of the vessel; detecting the presence of one or more markers in the sample; and an indication of at least the least one of the one or more markers in the subject.

BRIEF DESCRIPTION of DRAWINGS

[0006] Figure 1 is a fragmentary schematic illustration in cross section the construction of a toothbrush according to a variant embodiment of the invention.

DETAILED DESCRIPTION

[0007] Some embodiments of the present invention provide a device for identifying the presence of pathological conditions of the oral cavity, comprising: a vessel to sample from the oral cavity; a detector capable of detecting the presence of the marker in the sample; and an indicator that is able to trigger due to the signal from the detector. In other embodiments, implementation, vessel attached with the possibility of removing the facilities to care for the oral cavity. In other embodiments, the implementation, the vessel contains bioadhesive substance.

[0008] In some embodiments, the implementation of the vessel contains a collecting element and the reservoir. In some embodiments, the implementation of the collecting element collects a sample from the oral cavity. In some embodiments, the implementation of the reservoir stores the sample from the oral cavity. In some embodiments, the implementation of the vessel comprises a passage for fluid connecting with the possibility of passage of the fluid collecting member with the reservoir for providing a fluid environment of the oral cavity into the reservoir. In some embodiments, the implementation of detector is located inside the vessel. In certain embodiments of the implementation of the indicator is located inside the vessel.

[0009] In some embodiments, the implementation of the detector is located inside the tank. In some embodiments, the implementation of the indicator is located inside the tank.

[0010] Figure 1 schematically illustrates the toothbrush 100 having a collecting element 200 and the reservoir 155 is provided for storing a fluid environment of the oral cavity, such as saliva and/or a mixture of saliva and dental tools. In some embodiments, the implementation of the reservoir 155 may be provided in a narrow section 105 of the toothbrush 100 or at the distal end of the handle 103 toothbrush.

[0011] In some embodiments, the implementation of the passage 140 to the fluid, such as a capillary channel that extends in the longitudinal direction of the toothbrush 100 for delivery of the sample from the oral cavity into the reservoir 155 at least one inlet 150. In some embodiments, the implementation of the channel 140 uses capillary action to draw the sample from the inlet 150 to the reservoir 155. In some embodiments, the implementation of the capillary channel 140 has a capillary structure. In some embodiments, the implementation, the channel 140 is formed from a porous material. Examples of porous materials include fibrous materials, ceramics, porous plastics, such as plastic, available from Porex Technoogies, Atlanta, Georgia. In one example, the fibrous material is an acrylic material, known as model number C10010 available from Teibow Hanbai Co., Ltd., Tokyo, Japan. In some embodiments, the implementation can be provided by a mixture of porous and/or fibrous materials, which have a distribution of larger and smaller capillaries. In some embodiments, the implementation of the channel 140 can be formed from a number of small capillaries, which are connected to each other, or in the form of a larger single capillary tube.

[0012] In some embodiments, the implementation of the sample in the reservoir 155 examined for the disease, disorder or condition of the oral cavity, which can be detected through examination of the oral cavity.

[0013] In some embodiments, the implementation of the tank contains a replaceable cartridge. In some embodiments, the implementation of the vessel further comprises a receiving device, connected to the collecting element is configured to receive sample from the oral cavity.

[0014] In some embodiments, the implementation of a passage for the fluid contains fibrous material, ceramics, porous material or a combination thereof, to provide a capillary extract the sample from the oral cavity.

[0015] In some embodiments, the implementation of the sample is saliva, gingival crevicular ecost or fabric. In some embodiments, the implementation of a token is a sign of poor oral care mouth. In other embodiments, the implementation of a marker selected from the group consisting of: IL-Ιβ, PGE2, arginine, and gingipain.

[0016] In some embodiments, the implementation of the indicator is a dye. In some embodiments, the implementation of the indicator is expended after a single case detection. In some embodiments, the implementation of the indicator is a structural indicator.

[0017] In some embodiments, the implementation belonging for the care of the oral cavity is a toothbrush. In other embodiments, the implementation belonging for the care of the mouth is dental floss.

[0018] In some embodiments, the implementation of the vessel, the detector and the indicator is placed inside the patch. In other embodiments, the implementation, the patch may be attached to the surface of the oral cavity.

[0019] Some embodiments of the presented invention provides a method of identifying the presence of pathological conditions of the oral cavity of a subject, comprising: collecting a sample from the oral cavity of a subject with the use of the vessel; detecting the presence of one or more of the tokens in the specified form; and the indication of at least one of the one or more markers in the specified entity.

[0020] In some is the option of implementing the sample is saliva, gingival crevicular fluid or tissue.

[0021] In some embodiments, the implementation of the vessel contains a filter. In some embodiments, the implementation of the receptacle attached with the possibility of removing the facilities to care for the oral cavity. In other embodiments, the implementation, the vessel contains bioadhesive substance.

[0022] In other embodiments, the implementation of at least one of the one or more markers is a sign of poor oral care mouth. In additional embodiments, the implementation of at least one of the one or more markers selected from the group consisting of: IL-Ιβ, PGE2, arginine, and gingipain.

[0023] In some embodiments, the implementation of the indicator is a dye. In other embodiments, the implementation, the indicator used after single case detection. In some embodiments, the implementation of the indicator is a structural indicator. In some embodiments, the implementation of the indicator is to demonstrate the presence of specific marker directly after exposure to the marker. In some embodiments, the implementation of the indicator is to demonstrate the presence of specific marker approximately 2 days after exposure to the marker. In other embodiments, implementation of the indicator is to demonstrate the presence of specific marker after it was discovered the threshold is the line number of the token.

[0024] In additional embodiments, the implementation belonging for the care of the oral cavity is a toothbrush. In some embodiments, the implementation belonging for the care of the mouth is dental floss. In some embodiments, the implementation belonging for the care of the mouth is dental needle. In some embodiments, the implementation belonging for the care of the mouth is the tongue scraper.

[0025] In some embodiments, the implementation of the vessel, the detector and the indicator is placed within the sole structure. In some embodiments, the implementation of the design, inside the vessel, the detector and the indicator is zeolite or patch. In some embodiments, the implementation of the vessel, a detector and an indicator placed inside the patch. In some embodiments, the implementation of the patch may be attached to the surface of the oral cavity.

[0026] In some embodiments, the exercise device is a separate device, to be used separately from the facilities to care for the oral cavity. In some embodiments, the exercise device may be embedded in a larger structure, which is placed on one or more teeth. In some embodiments, the exercise device is inserted into the bracket, Kapu, dentures, or other device, performed with the who what and is very useful for placing in the mouth or over one or more teeth for an extended period of time.

[0027] In other embodiments, implementation of the indicator contains a flavouring substance. In additional embodiments, the implementation, the indicator is a structural indicator. In some embodiments, the structural indicator provides an indication of the subject, that in the mouth there is a specific marker. In some embodiments, the implementation of the token is specific to a particular disease, condition or disorder. In some embodiments, the structural indicator is felt on palpation of the subject. In some embodiments, the structural indicator is visually distinguishable to the subject. In some embodiments, implementation of the structural indicator is the hole. In other embodiments, the structural indicator is the crest.

[0028] In some embodiments, the implementation of the detector contains one or more polymers. In this area known suitable polymers, including polymers, described by Etienne O et al. (Polyelectrolyte multilayer film coating and stability at the surfaces of oral prosthesis base polymers: an in vitro and in vivo study. J Dent Res. 2006 Jan., 85(1): 44-8), moreover, this document is included in this application by reference in its entirety.

[0029] In some embodiments, the implementation of the indicator is isolated from the fluid and/or air in the oral cavity. In some embodiments assests is of light may not be visible immediately after the detection of the marker. In some embodiments, the implementation in order to become visible indicator requires continuous presence of the token.

[0030] In some embodiments, the implementation of pathological conditions of the oral cavity, identified using the devices described in this application include, but without limitation, pathological conditions associated with poor care for the oral cavity, pathological conditions that can be diagnosed through examination of the oral cavity and systemic pathological conditions, which have been installed or otherwise identified by the American Dental Association, correlate with poor care for the oral cavity.

[0031] In some embodiments, the implementation of a disease selected from the group consisting of: cavities, gingivitis, periodontitis, halitosis and dry mouth. In some embodiments, the implementation of markers for gingivitis are IL-Ιβ, PGE2, arginine and gingipain. In other embodiments, the implementation of gingivitis identified by elevated levels of one or more of P. gingivalis, C. gingivalis, P. melaninogenica, Treponema denticola, Bacterioides forsythus and S. mitis. In some embodiments, the implementation of halitosis is detected due to the presence in the oral cavity of volatile sulfur compounds, including methyl mercaptan, dimethyl sulfide and hydrogen sulfide.

[0032] In some embodiments, implementation, p is rightit detected due to the presence in the oral cavity elastase, dipeptidylpeptidase, β-glucuronidase, lactoferrin, platelet activating factor (PAF), ICPT (carboxyterminal cross-linking telopeptide), cathepsin B (cysteine protease), cystatins, MMP-1, collagenase-2 (matrix metalloproteinase, MMP-8), MMP-13 (collagenase-3), gelatinase (MMP-9), hydroxyl-deoxyguanozine and immunoglobulins, such as IgA, IgG and IgM.

[0033] In other embodiments, the implementation of presence related to bone metabolism biomarkers, such as calprotectin, osteocalcin, osteocalcin, osteopontin associated with periodontal disease. In some embodiments, the implementation of caries is detected due to the low pH of the saliva, the local pH (i.e., in specific locations on the solid tissue) and an acid generating bacteria of the oral cavity (specifically species of Lactobacillus, Streptococcus mutans and Actinomyces species).

[0034] In some embodiments, the implementation with unpleasant mouth odor associated systemic pathological conditions, unrelated to the oral cavity. In some embodiments, the implementation associated with unpleasant breath systemic diseases, not related to the oral cavity are: chronic liver failure; infections of the lower respiratory tract (bronchial and lung infections; infections of the kidneys and renal failure; and trimethylaminuria (the"syndrome of fish odor") (with the. link: Tangerman A. Halitosis in medicine: a review. Int Dent J. 2002 Jun; 52 Suppl 3:201-6). In some embodiments, the implementation of the marker can be detected in the exhaled gases. In some embodiments, the implementation of high concentrations of acetone (known as "acetone breath") in the breath of subjects indicate diabetic ketoacidosis.

[0035] In some embodiments, the implementation of systemic disease, disorder or condition can be a pathological condition of a person, inflammation or cancer. In some embodiments, the implementation of the marker is bacterial metaboliceski marker, such as markers, described in PCT/US2009/039184;, which is incorporated in this application by reference in its entirety.

[0036] In some embodiments, the implementation of the intensity of the color displayed by the indicator correlates with the severity or spread of the disease or disorder. In some embodiments, the implementation of a dye selected from the group consisting of: tetrazine, amaranth, red charming as erythrosine B, Indigo Carmine, brilliant blue FCF, betacarotene, persistent green FCF, erioglaucine disodium salt, curcumin, chromotrope FB, Kostyleva red And Riboflavin 5 monophosphatase salt, Riboflavin, betanin, lycopene, chocolate brown HT, brilliant black BN, green S, Indochina, bixi is a, cochenillifera red And amaranth, carmoisine of azorubine, cochineal and yellow FCF sunset.

[0037] it Should be taken into account that although the invention has been described in conjunction with specific variants of its implementation, the above description is intended to illustrate but not to limit the scope of the claims of the invention. Other aspects, advantages and modifications will become apparent to qualified experts in the field to which the invention relates, and data aspects and modifications are within the scope of the claims of the invention described and claimed in this document.

1. Device to identify the presence of diseases of the oral cavity of a subject, comprising:
a vessel for collecting a sample from the oral cavity;
a detector capable of detecting the presence of a marker in said sample;
the indicator is able to trigger due to the signal from the detector, characterized in that the said vessel attached with the possibility of removing the means to care for the oral cavity and contains:
collecting element (200) for collection of the sample from the oral cavity; and
tank (155) for storing the above-mentioned sample; in fact the indicator is located inside the above-mentioned tank (155); and
passage (140) for the fluid formed from fibrous Mat is the Rial, ceramic, porous plastic, or combinations thereof connecting with the possibility of passage of the fluid collecting element (200) with the tank (155), for supplying the sample to the reservoir (155) due to capillary action, and the said sample is saliva or gingival crevicular liquid.

2. The device under item 1, in which the said vessel contains bioadhesive.

3. The device under item 1, in which the said detector is located inside the above-mentioned tank (155).

4. The device under item 1, in which the said marker is indicative of poor oral care mouth.

5. The device under item 1, in which the said marker is selected from the group consisting of: IL-Iβ, PGE2, arginine, and gingipain.

6. The device under item 1, in which the said indicator is a dye.

7. The device under item 1, in which the said indicator is exhausted after a single case of detection.

8. The device under item 1, in which the said indicator is a physical indicator.

9. The device under item 1, in which the said means to care for the oral cavity is a toothbrush.

10. The device under item 1, in which the said means to care for the oral cavity is dental floss.

11. The device under item 1, in which the said vessel, a detector and an indicator placed inside the patch.

12. The device according to p. 11 in which the said place is yr can be attached to the surface of the oral cavity.

13. The method of identifying the presence of disease of the oral cavity of a subject, including:
collect sample from the oral cavity of a subject with the use of the vessel;
the detection of the presence of one or more markers in said sample; and
indication of the presence of at least one of the said one or more markers in said subject, characterized in that the said vessel attached with the possibility of removing the means to care for the oral cavity and contains:
collecting element (200) for collection of the sample from the oral cavity; and
tank (155) for storing the above-mentioned sample; in fact the indicator is located inside the above-mentioned tank (155); and
passage (140) for fluid connecting with the possibility of passage of the fluid collecting element (200) with the tank (155), for supplying the sample to the reservoir (155) due to capillary action, and the said sample is saliva or gingival crevicular liquid.

14. The method according to p. 13 in which the said vessel contains bioadhesive substance.

15. The method according to p. 13 in which the said detector is located inside the above-mentioned tank.

16. The method according to p. 13, in which at least one of the said one or more markers indicate poor care for the oral cavity.

17. The method according to p. 16, in which at least one of the mentioned one is or more markers selected from the group consisting of: IL-Iβ, PGE2, arginine, and gingipain.

18. The method according to p. 13, in which the said indicator is a dye.

19. The method according to p. 13 in which the said indicator is exhausted after a single case of detection.

20. The method according to p. 13, in which the said indicator is a structural indicator.

21. The method according to p. 13, in which the said means to care for the oral cavity is a toothbrush.

22. The method according to p. 13, in which the said means to care for the oral cavity is dental floss.

23. The method according to p. 14, in which the said vessel, a detector and an indicator placed inside the patch.

24. The method according to p. 23 in which the said patch can be attached to the surface of the oral cavity.

25. The device under item 1, for use in the method of identifying the presence of disease of the oral cavity of the subject.



 

Same patents:

FIELD: medicine.

SUBSTANCE: technique involves the clinical-laboratory examination of a sportsman who completed heavy physical activity 12-16 hours ago. The examination extent is determined taking into account the organs and systems most vulnerable to the physical activity while deriving the prognostically significant criteria of the morphofunctional body state. The examination involves measuring and analyzing the biochemical, haematological, immunological and functional values, as well as vitamin-mineral saturation. And if the above values are stably unchanged, reliably different from the norm, nonspecific changes of the sportsman's organs and systems are diagnosed.

EFFECT: technique provides the early diagnosis of the significant changes of the organs and systems during trainings and competitions that enables taking further timely measures to prevent the further progression of pathological conditions and maintaining thereby occupational performance and achieving stable high sport results.

FIELD: biotechnology.

SUBSTANCE: efficiency of treatment of patients with high grade non-Hodgkin malignant lymphoma is determined by the likelihood of achieving remission, and 5-year total and relapse-free survival. The method comprises the study of polymorphism G13494A 6th intron of gene TP53 of the patient. In case of revealing in the patient of homozygous genotype G/G in a given locus the low efficiency of treatment is predicted, namely, low likelihood of 5-year survival of the patient and low likelihood of absence of relapse. In the case of revealing in the patient of the genotype A/A or G/A in a given locus, the high efficiency of treatment is predicted, namely the high likelihood of remission and 5-year survival of patient.

EFFECT: invention enables to assess the efficiency of treatment of patients with high grade non-Hodgkin malignant lymphoma on the degree of polymorphism G13494A of 6th intron of gene TP53.

5 dwg, 10 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: invention represents a diagnostic technique for the disturbed thrombocyte aggregation accompanying mucoviscidosis in children involving a thrombocyte aggregation test using the Multiplate aggregometer inducers. Trays with a magnetic mixer and electrodes are added with NaCl 400 mcl at 37°C and immediately added with whole blood 400 mcl from a hirudin test tube, incubated in the chamber for two minutes; the tray is added with 30 mcl of an aggregation inducer specified in a group: soluble thrombin receptor - peptid-6, adenosine diphosphate, arachidonic acid. The thrombocyte aggregation rate is displayed on the screen in the form of a curve, and the sub-curve area U is automatically calculated; the sub-curve area U shows the thrombocyte aggregation state as compared to reference values in the group of healthy children; if the threshold area U has appeared to exceed the reference, the thrombocyte hyperaggregation, while the threshold area U being less than the reference, the thrombocyte hypoaggregation is stated.

EFFECT: invention provides the timely diagnosis of microcirculatory disorders accompanying mucoviscidosis.

2 ex, 1 dwg

FIELD: chemistry.

SUBSTANCE: invention relates to the field of microbiology, namely to a method of microorganism characteristic. The essence of the method consists in the following: (a) obtaining a sample to be tested, about which it is known that it contains or can contain microorganisms; (b) layering the tested sample on a density buffer in a container, where the said density buffer possesses a uniform density from approximately 1.025 to approximately 1.120 g/ml; (c) addition of an identifier into the said tested sample and/or into the said density buffer; (d) centrifugation of the said container in order to separate microorganisms from other components of the said tested sample and to form a deposit of microorganisms; (e) spectroscopic analysis of the deposit and/or the said one or more than one identifier with obtaining measurements, which characterise the microorganisms, where the said spectroscopic analysis is carried out when the said deposit is located in the said container; and (f) characteristic of the microorganisms in the deposit on the basis of the obtained measurements and/or the presence or absence of the said identifier or a metabolised form of the said identifier in the deposit, where the said microorganisms are characterised by one or more classification models, selected from the group, consisting of Gram groups, clinical Gram groups, therapeutic and functional groups.

EFFECT: application of the claimed invention makes it possible to increase the accuracy of the microorganism characteristic.

15 cl, 5 dwg, 1 tbl, 4 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to qualitative differential instant diagnostic technique for benign and malignant periglottis new growths as shown by oral fluid biomarkers. Substance of the method consists in measuring a quantity of matrix metalloproteinase 2 (MMP 2) in patient's oral fluid; the clinical reference is the level of 1.7-2.9 ng/ml; if the MMP 2 content is 14.4-24.3 ng/ml, patient's periglottis papilloma is diagnosed; if the patient's oral fluid MMP 2 content is 4.1-6.8 ng/ml, periglottis cancer is diagnosed. A biomarker for the qualitative differential instant diagnosis of the periglottis new growths is a tissue inhibitor of metalloproteinase 2 (TIMP 2); the clinical reference is a level of 6.44-11.23 ng/ml; if the TIMP 2 content 29.25-48.75 ng/ml, patient's periglottis papilloma is diagnosed; the TIMP 2 content being 57.23-95.03 ng/ml, periglottis cancer is diagnosed.

EFFECT: using the declared technique enables providing more accurate differential diagnosis of the benign and malignant periglottis new growths.

2 cl, 6 ex

FIELD: medicine.

SUBSTANCE: method is implemented by preparing an incubation solution No.1 containing sulphanilic acid 500 mg in 1 M HCl 50 ml, and solution No.2 consisting of NaNO2 125 ml in distilled water 2.5 ml. Each solution is taken in an amount of 1 ml, mixed in a test tube and added with whole blood with a coagulate 200 mcl. The reaction is carried out for 10 min at a room temperature, and a drop of the suspension is used to produce a multilayer smear on a slide, dried and studied by computed cytophotometry.

EFFECT: more accurate determination.

2 dwg

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely diagnostics and can be used for assessing threatened foetal death following the aggravated cytomegalovirus infection at the early stages of gestation. To this effect, with the underlying cytomegalovirus infection, peripheral blood of a pregnant woman is analysed to measure the anti-cytomegalovirus IgG antibody titre and progesterone level. If the anti-cytomegalovirus IgG titre is 1:1600, and the progesterone level is 18.5±0.8 nmole/l, a threatened spontaneous miscarriage is stated.

EFFECT: method enables stating the threatened spontaneous miscarriage if any at the early stages of gestation.

FIELD: medicine.

SUBSTANCE: invention refers to medicine, and represents a method for the prediction of a risk of congenital infections by measuring specific Ig M and Ig G antibodies in a biological material, differing by the fact that the biological material is presented by the first-screening cervical smear at the 12th week of gestation; the smears are tested for the IgG antibodies to the rubella virus, cytomegalovirus, B19V parvovirus, toxoplasm viruses, type 1 and 2 herpes simplex viruses and an avidity of the specific Ig G to this agents; additionally, the same smear is tested for secretory non-specific Ig A by IFA to cytomegalovirus, Chlamydia, Mycoplasm antigens, and a genetic material of this microorganisms by PCR, and depending on the findings, groups of a high, moderate and low risk of congenital infections are predicted.

EFFECT: invention provides the more accurate prediction of the risk of the most actual congenital infections by the integral assessment of a collection of clinical anamnestic data, and the qualitative parameters of the laboratory findings at the first pregnancy screening.

3 ex

FIELD: medicine.

SUBSTANCE: invention aims at assessing an efficacy of therapeutic agents (TA) for improving individual's cognitive functions. The patient's blood serum is examined for the HLDF protein, titres of idiotypic and anti-idiotypic HLDF antibodies before and after the TA is administered, and the above derived data are used to calculate MMSE before and after the TA is administered by formula; the derived MMSEs are compared, and the TA efficacy is assessed by the comparison result.

EFFECT: invention enables more real-time selection of one or another TA or the length of the course of administration, including the real-time prescription of this course if the patient's condition deteriorates.

3 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: invention can be used to assess a risk of cervical cancer accompanying cervical intraepithelial neoplasia and a human papilloma virus (HPV) carrier state in fertile females. That is ensured by sampling cells from the exocervical surface to recover RNA and measuring the gene mRNA expression levels: MKI67, CDKN2A, PGR, BAX. Relating the mRNA expression levels provides calculating a linear discriminant function (LDF): LDF=1.2*lg[CDKN2A]/[BAX]-lg[PGR]/[MKI67]-1, wherein [CDKN2A]/[BAX] is the relation of the CDKN2A and BAX mRNA expression levels, [PGR]/[MKI67] is the relation of the progesterone receptor and MKI67 mRNA expression levels, and if LDF≤0, a low risk of neoplastic transformation is stated; LDF>0 shows a higher risk of neoplastic transformation.

EFFECT: method enables assessing a risk of cervical cancer by the representation of reference genes mRNAs.

2 dwg, 1 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine and can be used in determining the tumour sensitivity to a chemopreparation. The preparation is presented with a material taken from the tumour. The preparation is coated with a solution consisting of normal saline and the chemopreparation taken in a ratio of 4500: per a single dose of the analysed chemopreparation. That is followed by Romanowsky-Giemsa staining of the preparation 1-2 hours later. The preparation sensitivity is stated if any malignant cells are found in the preparation.

EFFECT: method provides the rapid, accessible and effective determination of the tumour sensitivity to the chemopreparation by using the optimal concentration of the chemopreparation solution and available staining.

3 ex

FIELD: medicine.

SUBSTANCE: technique involves the clinical-laboratory examination of a sportsman who completed heavy physical activity 12-16 hours ago. The examination extent is determined taking into account the organs and systems most vulnerable to the physical activity while deriving the prognostically significant criteria of the morphofunctional body state. The examination involves measuring and analyzing the biochemical, haematological, immunological and functional values, as well as vitamin-mineral saturation. And if the above values are stably unchanged, reliably different from the norm, nonspecific changes of the sportsman's organs and systems are diagnosed.

EFFECT: technique provides the early diagnosis of the significant changes of the organs and systems during trainings and competitions that enables taking further timely measures to prevent the further progression of pathological conditions and maintaining thereby occupational performance and achieving stable high sport results.

FIELD: medicine.

SUBSTANCE: clinical medical history data are determined as follows: body weight index (BWI), kg/m2; waist circumference (WC), hip circumference (HC), waist-to-hip ratio, type 2 diabetes mellitus diagnosed in close relatives, arterial hypertension (AH) diagnosed. The laboratory data are measured as follows: plasminogen activator inhibitor-1 (PGAI-1), nmole/l; nitrogen oxide (NO) metabolites, %; resistin, ng/ml; insulin resistance (IR), mIU/ml; triglycerides (TG), mmole/l; high density lipoprotein cholesterol (HDLPC), mmole/l; fibrinogen, mg/dl; impaired fasting glucose (IFG), mmole/l; glycosylated haemoglobin (HbAlc), %; impaired glucose tolerance (IGT), mmole/l; homocystein (HC), mcmole/l; TNF-α, pg/ml; C-reactive protein, mg/l; endothelin and fibrinogen. The derived values are scored. The total score is used to determine a risk of atherosclerosis in the patients suffering from type 2 diabetes mellitus: extremely high, high, moderate and low. Taking into account the detected degree of risk, a dosage of aspirin and statins are determined, as well as a monitored mode of blood lipids, urinary albumin and blood creatinine is specified.

EFFECT: method enables determining a degree of risk of the atherosclerosis progression as shown by the clinical medical history and laboratory data, as well as specifying individual pathogenetic therapy for the patient that leads to reducing developing cardiovascular complications.

4 tbl, 1 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to surgery. A biopsy is performed, and a bipolar drain tube is inserted into the bile ducts. A terminal end of the X-ray contrast drain tube is preliminarily notched along the long axis. A recurrent biopsy is performed on the 10-14th day. The external drain tube is removed. The biopsy forceps 3.5 cm is inserted along a fistulous passage. The bile ducts are contrasted by inserting a thin X-ray contrast catheter guide. A histological material is sampled under X-ray control.

EFFECT: method for the direct punch biopsy of the tumour along the fistulous passage reduces injuries and provides the higher diagnostic accuracy.

2 ex, 9 dwg

FIELD: medicine.

SUBSTANCE: invention refers to medicine, and can be used to diagnose pulmonary thromboembolism. Computed-tomography pulmonary angiography is performed. Complementary scanning is performed on the 30th second from administering a contrast agent. That is followed by a post-processing preparation of the scanning findings. The preparation involves a visual assessment of the vessels and lung parenchyma taking into account the measured density of the lung parenchyma on the 30th second after administering the contrast agent in the segment of the estimated hypoperfusion or aperfusion and in the intact region at the identical level in HU. The P1/P2 relation is calculated, wherein P1 is the density of the lung parenchyma after administering the contrast agent in the pulmonary artery in the segment of the estimated hypo- or aperfusion (HU), P2 is the density of the lung parenchyma in the intact region. If the P1/P2 relation is less than 0.2, pulmonary thromboembolism is diagnosed.

EFFECT: technique provides the higher accuracy, effectiveness and information value of diagnosing pulmonary thromboembolism by complementary scanning and assessment of the relation of the density of the lung parenchyma measured at complementary scanning and in the intact region.

1 dwg, 3 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, particularly to dentistry, and can be used to predict recurrent caries in pregnant women. The previous medical history of the pregnant woman in the first trimester of pregnancy is studied, and her oral cavity is examined. The previous medical history is used to determine: the number of pregnancies (NP) including the present one, the order number (ON) of the forthcoming delivery, pregnancy complications factor (PCF) which is assigned with a value of 1 if the patient has one or more complications of the present pregnancy, while the absence of complications enables assigning the value of 0. The oral cavity examination findings are used to determine the caries intensity - CFE. CFE=C+F+E, wherein C is the number of carious - uncured teeth at the moment of examination, F is the number of filled - cured teeth at the moment of examination, E is the number of extracted or to be extracted teeth. That is followed by calculating a prediction coefficient (PC) by formula: PC=-0.5+0.031×NP+0.127×ON+0.177×PCF+0.066×CFE. Providing the condition K≥0.7, recurrent caries is predicted.

EFFECT: method enables the reliable prediction.

2 ex

FIELD: medicine.

SUBSTANCE: vascular wall analysis device is provided by a structure enabling the accurate measurement of components of a vascular wall plaque in a state, which reduces a patient's load. When analysing the vascular wall, a measuring light is emitted on a measured segment inside the vascular wall, e.g. a carotid, from a light emission unit mounted inside the vascular wall, whereas the light from the measured segment is detected by the light receiver unit provided outside the vascular wall. The state of the vascular wall can be analysed without inserting the device used for the measurement into the blood vessel. In addition, the measuring procedure with using a near infrared light (a light component within the range of 780 nm to 2750 nm), which shows characteristics differing by the composition of substances, e.g. the plaque attached to the inside of the blood vessel, results in the analysis aimed at identifying various components, e.g. plaques with the use of the analysis device provided outside the blood vessel.

EFFECT: reducing the patient's load during the measurement procedure.

21 cl, 13 dwg

FIELD: oil and gas industry.

SUBSTANCE: treating bronchial asthma (BA) in a child suffering from a mild, moderate or severe episode involves measuring a peak expiratory flow rate (PEFR). The child's age, height and sex are stated. The derived data are used to determine the adequate peak expiratory flow rate. That is followed by calculating the peak expiratory flow rate coefficient by specific formula. The following data of the past medical history are taken into account: the child's duration of the disease, the length of basic therapy, completed months, for one year preceding the acute period of the disease, as well as the presence of allergic diseases in immediate maternal and paternal relatives. A severity of the BA episodes is assessed. Each value derived from the past medical history is assigned with numerical values reflecting their prognostic significance. Heart rates are measured. Cardiointervalography is performed, and a vagosympathetic balance coefficient is determined. That is followed by calculating a risk of cardiohaemodynamic disorders (CHD) taking into account the above criteria by specific formula. If CHD<0.34, Fenoterol selective β2-adrenoceptor agonist is selected as a bronchial spasmolytic in the acute period of the disease. If 0.34≤CHD≤0.46, ipratropium bromide m-cholinoblocker is selected as the bronchial spasmolytic. If CHD>0.46, combined ipratropium bromide + Fenoterol is used as the bronchial spasmolytic.

EFFECT: reduced number of cardiovascular complications in the above category of children.

3 part-s

FIELD: medicine.

SUBSTANCE: device comprises a laser light source, a light guide connected thereto, a biopsy cannula connected to a Luer adapter through a second input of which an optical fibre from the laser light source and at least one receiving fibre extend and are fixed in the cannula and a third input of which is configured for a syringe which is used to draw a biopsy material into the cannula; there are also provided spectrometer unit with a fibre-optic light input, personal computer.

EFFECT: continuous spectroscopic inspection of parenchymal tumour biopsy procedure without standard disorders of the given operation and without prolonging the procedure in general.

3 dwg

FIELD: medicine.

SUBSTANCE: 4-6 months after the 4g-loaded orbiter mission and descent, on the first post-mission day an astronaut is dressed in a space suit at a nominal excessive pressure and total weight of the astronaut and space suit of 0.38 of this weight on the Earth. Thereafter, the astronaut carries out some work on the Mars surface which involves recording an astronaut heart rate (HR); once reaching individually acceptable thresholds, the physical actions are interrupted for the heart rate recovery to individually recommended medical parameters. Total pause duration is subtracted from total working hours. A difference is defined as net working hours. If the net working hours is equal to or exceed a minimum time required for the minimum time it takes for performing Mars surface operations, a performance level is considered to be satisfactory.

EFFECT: method enables ground prediction of astronaut's professional performance after the space travel and Mars landing by simulating the Mars orbital environment.

1 tbl

FIELD: personal use articles.

SUBSTANCE: proposed is a toothbrush containing a head (having a longitudinal axis extending from the proximal end of the head to its distal end), a handle connected to the proximal end of the head and extending therefrom emerging from the head surface and including multiple groups of elastomer walls that jointly form closed configurations positioned along the head longitudinal axis. The elastomer walls within each group are separated with a gap with each closed configuration containing a gap positioned on the longitudinal axis of the head, central cleaning elements positioned inside each closed configuration and multiple bristles positioned outside the closed configurations.

EFFECT: convenience of use.

20 cl, 7 dwg

Up!